Fig. 3.

Combining UBR5 and CD163⁺ TAMs better predicts prognosis of ccRCC patients. a Representative images of H&E and IHC staining of UBR5 and CD163 in ccRCC specimens are shown (n = 310; scale bar = 20 µm). b The correlation analysis between UBR5 and CD163 in ccRCC specimens is shown. c A time-dependent ROC analysis was applied to calculate the optimum cutoff value of CD163 to predict 5-year OS in the training cohort (3:2 ratio). d–g Kaplan–Meier curves for OS and PFS of ccRCC patients were analyzed based on the expressions of UBR5 and CD163 in the training cohort (d, e) and the validation cohort (f, g) (3:2 ratio). h A time-dependent ROC analysis was used to examine the optimum cutoff value of CD163 to predict 5-year OS in the training cohort (1:1 ratio). i–l Kaplan–Meier curves for OS and PFS of ccRCC patients were analyzed according to expressions of UBR5 and CD163 in the randomized training cohort (i, j) and validation cohort (k, l) (1:1 ratio). m A time-dependent ROC analysis was used to examine the optimum cutoff value of CD163 to predict 5-year OS in the combined cohort. n–o Kaplan–Meier curves for OS and PFS of ccRCC patients were analyzed based on the expressions of UBR5 and CD163 in the combined cohort. All p values are defined as: *p < 0.05; **p < 0.01 and ***p < 0.001